Agentix (AGTX) Non-Current Assets (2014 - 2019)
Agentix's (AGTX) quarterly Non-Current Assets came in at $8.0 in Q1 2019, down 97.06% YoY from $272.0 in Q1 2018, and down 89.19% on a QoQ basis from $74.0 in Q4 2018.
Agentix (AGTX) Non-Current Assets (2014 - 2019) Analysis & Trends
Agentix (AGTX) has 6 years of Non-Current Assets data on file, last reported at $8.0 in Q1 2019.
- Quarterly Non-Current Assets fell 97.06% year-over-year to $8.0 in Q1 2019, while the trailing twelve-month figure through Nov 2019 was $8.0 (down 98.84% YoY) and the FY2018 annual result came in at $140.0, down 95.89% from the prior year.
- Non-Current Assets eased to $8.0 in Q1 2019, from $74.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $10602.0 in Q4 2016 to a low of $8.0 in Q1 2019.
- A 5-year average of $3575.4 and a median of $3371.0 in 2017 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2017 — Non-Current Assets jumped 1286.78% — and 2018, when it sank 97.98%.
- Tracing AGTX's Non-Current Assets over 5 years: stood at $4197.0 in 2015, then jumped by 152.61% to $10602.0 in 2016, then sank by 68.52% to $3338.0 in 2017, then sank by 97.78% to $74.0 in 2018, then plunged by 89.19% to $8.0 in 2019.
- The last three Non-Current Assets figures came in at $8.0 (Q1 2019), $74.0 (Q4 2018), and $140.0 (Q3 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Agentix | 801,339.00 | 801,301.00 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2019 | 8.00 |
| Nov 30, 2018 | 74.00 |
| Aug 31, 2018 | 140.00 |
| May 31, 2018 | 206.00 |
| Feb 28, 2018 | 272.00 |
| Nov 30, 2017 | 3,338.00 |
| Aug 31, 2017 | 3,404.00 |
| May 31, 2017 | 10,179.00 |
| Feb 28, 2017 | 10,536.00 |
| Nov 30, 2016 | 10,602.00 |
| Aug 31, 2016 | 668.00 |
| May 31, 2016 | 734.00 |
| Feb 29, 2016 | 4,068.00 |
| Nov 30, 2015 | 4,197.00 |
| Aug 31, 2015 | 4,326.00 |
| Feb 28, 2015 | 4,455.00 |
| Nov 30, 2014 | 4,584.00 |
| Aug 31, 2014 | 4,713.00 |